NAGE Niagen Bioscience, Inc.

8-K Current Report

Filed: March 19, 2026

Health Care

Medicinal Chemicals & Botanical Products

Niagen Bioscience, Inc. (NAGE) 8-K current report filed with SEC EDGAR on March 19, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• Board increased share repurchase authorization to $20M from prior $10M, doubling buyback capacity to return capital to shareholders
• $2.6M of stock repurchased through March 17, 2026, showing initial program uptake and market activity

+3 more insights

Other Niagen Bioscience, Inc. 8-K Filings

8-K Mar 4, 2026

8-K Feb 26, 2026

Get deeper insights on Niagen Bioscience, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.